| scholarly article | Q13442814 |
| P2093 | author name string | Andrei Goga | |
| Lionel Lim | |||
| Mark M Moasser | |||
| Dhara N Amin | |||
| Natalia Sergina | |||
| P2860 | cites work | Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2 | Q21145847 |
| Regulation of endothelium-derived nitric oxide production by the protein kinase Akt | Q22010149 | ||
| Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation | Q22010150 | ||
| EGFR/Met association regulates EGFR TKI resistance in breast cancer | Q24338635 | ||
| Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera | Q24595150 | ||
| Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 | Q24633878 | ||
| The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation | Q24678674 | ||
| Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3 | Q27646596 | ||
| Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases | Q27652488 | ||
| Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. | Q27851483 | ||
| Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas | Q28287906 | ||
| The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins | Q28507365 | ||
| The Akt kinase signals directly to endothelial nitric oxide synthase | Q28609847 | ||
| Epidermal growth factor receptor mutations in lung cancer | Q29615474 | ||
| Insulin signaling diverges into Akt-dependent and -independent signals to regulate the recruitment/docking and the fusion of GLUT4 vesicles to the plasma membrane | Q30445667 | ||
| Protein kinase B/Akt participates in GLUT4 translocation by insulin in L6 myoblasts | Q33651661 | ||
| ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines | Q33928631 | ||
| The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy | Q34325749 | ||
| The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics | Q34349389 | ||
| The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis | Q34493341 | ||
| AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity | Q34511038 | ||
| Resiliency and vulnerability in the HER2-HER3 tumorigenic driver | Q34551761 | ||
| ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells | Q34637108 | ||
| Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase | Q34720797 | ||
| microRNA-205 regulates HER3 in human breast cancer | Q34960615 | ||
| Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity | Q35684026 | ||
| Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors | Q35779022 | ||
| Membrane traffic: controlling membrane fusion by modifying NSF. | Q35959045 | ||
| The epidermal growth factor receptor family | Q36236606 | ||
| Signaling through ERBB receptors: multiple layers of diversity and control | Q36388160 | ||
| ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor | Q36653753 | ||
| Insulin resistance due to phosphorylation of insulin receptor substrate-1 at serine 302. | Q38340048 | ||
| HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy | Q39368710 | ||
| Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor. | Q39821682 | ||
| A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy | Q39960692 | ||
| A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. | Q39979475 | ||
| Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b | Q40207487 | ||
| The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3. | Q40281070 | ||
| Dominant negative interference of transcription factor AP-2 causes inhibition of ErbB-3 expression and suppresses malignant cell growth | Q40748909 | ||
| Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein | Q41120641 | ||
| SNAREs and NSF in targeted membrane fusion | Q41566661 | ||
| S-nitrosylation of NSF controls membrane trafficking. | Q44624356 | ||
| Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies | Q45067792 | ||
| Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells | Q54391771 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 417-425 | |
| P577 | publication date | 2012-11-01 | |
| P1433 | published in | Biochemical Journal | Q864221 |
| P1476 | title | HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells | |
| P478 | volume | 447 |
| Q36359705 | A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers |
| Q38238616 | A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy |
| Q36562299 | Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib |
| Q58112887 | Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer |
| Q47782406 | Computational Modeling of ERBB2 -Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors |
| Q34752052 | Development and characterization of small bispecific albumin-binding domains with high affinity for ErbB3. |
| Q33772914 | ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1) |
| Q33737298 | Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways |
| Q38864254 | ErbB3 upregulation by the HNSCC 3D microenvironment modulates cell survival and growth |
| Q35201923 | HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells |
| Q28551145 | HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B |
| Q37407344 | HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4). |
| Q38725101 | HER3 as a Therapeutic Target in Cancer |
| Q27853067 | HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models |
| Q55091931 | Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment. |
| Q92063336 | Overexpression of HER2/HER3 and clinical feature of ovarian cancer |
| Q42557873 | Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC. |
| Q41036589 | SNP rs3202538 in 3'UTR region of ErbB3 regulated by miR-204 and miR-211 promote gastric cancer development in Chinese population |
| Q35890128 | Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum |
| Q34036131 | Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation |
| Q41667670 | The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation |
| Q38766447 | The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation |
| Q36771985 | The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells |
| Q38214802 | Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic |
| Q38876630 | hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells. |
Search more.